BiomX launches cystic fibrosis trial, partners with Boehringer Ingelheim on new IBD effort
Photo | BiomX website
BiomX CEO Jonathan Solomon
BiomX, an Israeli bioscience firm with Branford operations, announced this week that it had begun dosing patients for a Phase 1b/2a clinical trial of one its drug candidates for the treatment of cystic fibrosis (CF).
The company, which makes engineered phage therapies that target pathogenic bacteria, is testing candidate BX004 for the treatment of chronic respiratory infections in CF patients.
BX004 targets Pseudomonas aeruginosa, an antibiotic-resistant bacterium that is a leading cause of illness and death in CF patients.
The first part of the study will assess the safety, pharmacokinetics and clinical activity of BX004 in eight CF patients, with results expected in the third quarter of 2022.
BiomX CEO Jonathan Solomon said, “We are pleased to reach this important clinical milestone in our cystic fibrosis program.”
In a news release on Tuesday, BiomX announced it would partner with pharma giant Boehringer Ingelheim to identify biomarkers for a bacterium implicated in inflammatory bowel disease (IBD).
BiomX first partnered with Boehringer Ingelheim in 2020 to identify biomarkers associated with patient phenotypes in IBD. Based in Germany, Boehringer Ingelheim has its U.S. headquarters in Ridgefield.
Under the terms of the new deal, BiomX will use its XMarker microbiome-based discovery platform to search for biomarkers for a pathogenic bacterium thought to be associated with IBD. The biomarkers could help identify IBD patients that would benefit from potential therapies targeted at the microbiome.
BiomX announced in May it would cut 50% of its workforce as part of a corporate restructuring.
Contact Liese Klein at lklein@newhavenbiz.com.
Most Recent
Most Recent
0 Comments